Development of a Novel PET Imaging Agent for Prostate Cancer


To produce a GMP-quality, novel metastatic prostate cancer targeted imaging agent product for use in a toxicology study to prepare for FDA review

Anticipated Impact: 

Significantly improved detection of metastatic prostate cancer


Metastatic prostate cancer cannot be diagnosed adequately and is associated with high mortality. Early identification of prostate cancer metastasis would enable more rapid and aggressive treatment and better patient outcomes. Cancer Targeted Technology has developed a highly specific, easily produced agent that can identify human prostate cancer cells implanted in an animal model through binding to prostate-specific membrane antigen (PSMA). This grant focuses on developing that agent for the diagnosis of metastatic prostate cancer via positron emission tomography (PET) imaging. Ultimately, the diagnostic could be radioactively labeled to act as a therapeutic and kill metastatic cells. LSDF funding will support manufacture of good manufacturing practice (GMP)-compliant material and toxicology studies in an animal model in preparation for human studies.

Collaborating organizations: Washington State University, PD Consulting, SNBL USA, Irix Pharmaceuticals, Ricerca Biosciences

Cancer Targeted Technology named Beatrice Langton-Webster as principal investigator, replacing Alisa Littau, in November 2013.

Prostate Cancer Detection, Biomarkers, Targeted Therapy

Grant Update

Principal Investigator:
Beatrice Langton-Webster
Grantee Organization:
Cancer Targeted Technology
Grant Title:
Development of a Novel PET Imaging Agent for Prostate Cancer
Grant Cohort and Year:
2013 Proof of Concept (03)
Grant Period:
05/01/2014 - 04/30/2016 (Completed)
Grant Amount:
Cancer Targeted Technology is developing a specific and sensitive PSMA-targeted non-invasive imaging diagnostic for prostate cancer (PCa) that can be radiolabeled in any one of the over 2271 PET imaging centers in the United States. The 18F -labeled PET agent, CTT1057, will be the first of its kind; quickly and accurately detecting metastatic PCa, leading to better staging and earlier diagnosis of PCa spread as well as guiding clinicians and patients to the most effective treatment regimens. CTT1057 binds to an extracellular region of the validated biomarker, Prostate-Specific Membrane Antigen (PSMA) and has several innovative and unique characteristics compared to what is available or in development including: 1. a desirable low molecular weight allowing for rapid biodistribution; 2. targeted binding characteristics to PSMA-expressing prostate tumor cells (low nanomolar affinity, irreversible binding and internalization-- supporting rapid imaging with excellent accuracy); 3. use of a short half- life 18F radionuclide and 4. a cost-effective manufacturing profile. Using LSDF grant funds, CTT accomplished two significant advancements in our IND-enabling program: Aim 1-Manufacture GMP-equivalent cold-standard test article for toxicity/TK evaluation and Aim 2-Conduct an IND- enabling GLP toxicity/toxicokinetic study in rats.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
9, 38, 40, 42, 45

Health Impacts

Prostate Cancer Detection, Biomarkers, Targeted Therapy